Home > Insider Trading > Filing (0001437749-17-002462)

Filing Details

Accession Number:: 0001437749-17-002462
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-02-14 17:33:05
Reporting Period:: 2017-02-10

Filing Date:: 2017-02-14
Accepted Time:: 2017-02-14 17:33:05
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
820081	Cambrex Corp	CBM	Pharmaceutical Preparations (2834)	222476135

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1192621	M Steven Klosk	One Meadowlnds Plaza East Rutherford NJ 07073	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2017-02-10	49,266	$52.62	109,062	No	4	S	Direct
Common Stock	Disposition	2017-02-10	1,912	$53.36	107,150	No	4	S	Direct
Common Stock	Acquisiton	2017-02-13	12,000	$5.72	119,150	No	4	M	Direct
Common Stock	Disposition	2017-02-13	11,900	$52.09	107,250	No	4	S	Direct
Common Stock	Disposition	2017-02-13	100	$52.75	107,150	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2017-02-13	12,000	$0.00	12,000	$5.72

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
88,000		2018-10-18	No	4	M	Direct

Footnotes

Broker-assisted sale of which 38,936 shares sold were to cover the payment of withholding tax liability arising from the settlement of a performance share award granted on February 7, 2017
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.25 to $53.20 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.35 to $53.40 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.73 to $52.70 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4
The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934
The option representing a right to purchase 100,000 shares became exercisable in four equal installments beginning October 18, 2012, which was the first anniversary of the date on which the option was granted